US EditionPublished • loading... • Updated
ADMA Biologics Inc (ADMA) Stock Analysis: Unpacking A 48% Potential Upside
Summary by DirectorsTalk Interviews
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
ADMA Biologics Inc (ADMA) Stock Analysis: Unpacking A 48% Potential Upside
In the dynamic realm of biotechnology, ADMA Biologics Inc (NASDAQ: ADMA) has carved out a niche with its specialty plasma-derived biologics, targeting immune deficiencies and infectious diseases. With a market capitalization of $4.13 billion, ADMA presents an intriguing proposition for investors eyeing growth potential in the healthcare sector. ADMA’s current stock price stands at $17.30, having experienced a modest change of 0.29 (0.02%) recent…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
